ArticleJournal of natural medicines2025
Eucommiae cortex extract alleviates renal fibrosis in CKD mice induced by adenine through the TGF-β1/Smad signaling pathway.
Article in Journal of natural medicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HOXA2 exerts anti-renal fibrosis effects through reducing endoplasmic reticulum stress via the upregulation of SIRT1.Communications biology · 2025Article
- Comparison of Anti-Renal Fibrosis Activity ofPharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Research into the potential therapeutic benefits of herbal remedies for treating chronic kidney disease (CKD), a condition marked by renal fibrosis and persistent inflammation, has become popular. Eucommiae cortex (EC) is a vital herb for strengthening bones and muscles and tonifying the kidneys and liver. In the study, C57 BL/6 mice were given a diet containing 0.2% adenine to create a CKD model. The findings demonstrated that exogenous EC supplementation successfully decreased the levels of creatinine and urea nitrogen, down-regulated the TGF-β1/Smad signaling pathway's expression levels of TGF-β1, α-SMA, Smad3, and phospho-Smad3, and prevented renal fibrosis. Consequently, it was determined that EC might have a nephroprotective impact.
Indexed as
Identifiers
39443397What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.